bioAffinity Technologies Inc BIAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.94–2.28
- 52-Week Range
- $1.90–80.70
- Bid/Ask
- $2.15 / $2.20
- Shares Outstanding
- 1.82M
- Market Cap
- $3.91M
- Volume/Avg
- 70,498 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
Valuation
Metric | BIAF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.64 |
Price/Sales | 0.18 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | BIAF |
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 1.51 |
Interest Coverage | −306.74 |
Quick Ratio
BIAF
Profitability
Metric | BIAF |
|---|---|
Return on Assets (Normalized) | −150.76% |
Return on Equity (Normalized) | −249.90% |
Return on Invested Capital (Normalized) | −204.08% |
Return on Assets
BIAF
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|Ywx!%rZ | LOCK|^#k | $257B | |||
| Danaher Corp DHR | LOCK|gh<<c#f | LOCK|&%q | $161B | |||
| IDEXX Laboratories Inc IDXX | LOCK|%$#<%?^& | LOCK|>v | $55B | |||
| Agilent Technologies Inc A | LOCK|<%GVcrM& | LOCK|Z?j | $50B | |||
| Waters Corp WAT | LOCK|ZVQM?M | LOCK|#>d | $46B | |||
| IQVIA Holdings Inc IQV | LOCK|X^FNx# | LOCK|Db&x% | $42B | |||
| Mettler-Toledo International Inc MTD | LOCK|Y$ZrS$& | LOCK|$q^$X | $35B | |||
| Illumina Inc ILMN | LOCK|D<^#XT | LOCK|<&@# | $32B | |||
| Labcorp Holdings Inc LH | LOCK|%@VR$^c | LOCK|^cDk | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|@Gm>$h | LOCK|dw$^ | $29B |